Deal for Catalent’s blow-fill-seal business now official

Leaders in the space discuss aspects of experimental drug support and more at this year’s US Pharma and Biotech Summit.

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

IQVIA report explores the latest spending tendencies in the United States, while providing additional clarity as to why COVID-19 vaccines and therapeutics continue to experience a decline in volume.

The acquisition, the parties say, will benefit pharma and biotech in the clinical and commercial stages.

Collaboration will be oncology based—centered around allogeneic CAR-T cell therapy product candidates—and will provide Poseida with up to $550 million if certain milestones are met.

Per the US strategic partnership agreement, the adalimumab high-concentration interchangeable biosimilar will be distributed under the Quallent Pharmaceuticals private label.